跳至主要内容
临床试验/NL-OMON39112
NL-OMON39112已完成2 期

A Study of Percutaneous Left Ventricular Reshaping of Mitral Apparatus to Reduce Functional Mitral Regurgitation and Improve LV Function Using the Accucinch System. - LV Restore Study

Guided Delivery Systems, Inc.0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Age >= 18 years
  • 2. Subjects with clinically significant mitral regurgitation (MR 2+ and above)
  • 3. Ejection Fraction >= 25%
  • 4. Stable cardiac medical regimen for heart failure for at least 1 month
  • 5. Stable NYHA Classification for at least 1 month
  • 6. Subject is eligible for cardiac surgery
  • 7. The subject has been informed of the nature of the study, agrees to its provisions, and has provided written consent

排除标准

  • 1. Myocardial infarction within 90 days of the intended treatment with the device
  • 2. Prior surgical, transcatheter, or percutaneous mitral valve intervention
  • 3. Any intervention for coronary artery disease (CAD) within the last 30 days prior to treatment, or unrevascularized multivessel coronary disease.
  • 4. Hemodynamic instability or the need for emergent surgery
  • 5. Non-ambulatory NYHA Class IV symptoms of heart failure or subjects requiring IV inotropic support
  • 6. Subjects in whom sufficient quality of echocardiography (TTE and TEE) cannot be obtained
  • 7. Echocardiography evidence of primary mitral valve disease causing MR or MS
  • 8. Evidence of mitral valve stenosis with an estimated valve area less than 3.0 cm²
  • 9. Mitral valve prosthesis or pathology that would prevent adequate function of the GDS Accucinch System
  • 10. Estimated GFR of <30ml/min/1.73m²
  • 11. Greater than mild mitral annular calcification observed by fluoroscopy
  • 12. Presence of aortic valve prosthesis
  • 13. Moderate to severe aortic valve stenosis or calcification observed by echocardiography or fluoroscopy
  • 14. Severe aortic arch calcification or mobile aortic atheroma observed by echocardiography or fluoroscopy
  • 15. Active bacterial endocarditis
  • 16. History of bleeding diathesis or coagulopathy
  • 17. History of stroke within the prior 6 months
  • 18. Subjects in whom anticoagulation is contraindicated
  • 19. Any clinical evidence that the investigator feels would place the subject at increased risk with the placement of the device
  • 20. Concurrent medical condition with a life expectancy of less than 12 months
  • 21. Currently participating in an investigational study
  • 22. Co-morbid conditions that place the subject at an unacceptable surgical risk (e.g. severe chronic obstructive pulmonary disease, hepatic failure, immunological abnormalities, and hematological abnormalities)
  • 23. Subjects with indication for concomitant surgery such as coronary artery bypass graft (CABG), aortic valve reconstruction or replacement, tricuspid repair or replacement, left ventricular remodeling surgery and congenital repair
  • 24. Any cardiac resynchronization therapy within the last 3 months prior to treatment
  • 25. Subjects on high dose steroids or immunosuppressant therapy
  • 26. Female subjects who are pregnant, of child bearing potential or lactating
  • 27. Subjects who are unable or unwilling to comply with the follow-up schedule and requirements

研究者

发起方
Guided Delivery Systems, Inc.

相似试验